Eusebio Chiefari

List of Publications by Year
in descending order

83	4,240	94269 37	118652 62
papers	citations	h-index	g-index

87	87	87	5941
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Plasma or Urine Neutrophil Gelatinase-Associated Lipocalin (NGAL): Which Is Better at Detecting Chronic Kidney Damage in Type 2 Diabetes?. Endocrines, 2022, 3, 175-186.	0.4	6
2	A Partial Phenotype of adFNDI Related to the Signal Peptide c.55G>A Variant of the AVP Gene. Endocrines, 2021, 2, 37-43.	0.4	1
3	Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes. Journal of Clinical Medicine, 2021, 10, 985.	1.0	22
4	Gestational diabetes: Implications for fetal growth, intervention timing, and treatment options. Current Opinion in Pharmacology, 2021, 60, 1-10.	1.7	44
5	Methods to Study Protein-Binding to Pseudogene Transcripts. Methods in Molecular Biology, 2021, 2324, 187-202.	0.4	2
6	Insulin Resistance and Cancer: In Search for a Causal Link. International Journal of Molecular Sciences, 2021, 22, 11137.	1.8	46
7	Long-Term Effectiveness of Liraglutide for Weight Management and Glycemic Control in Type 2 Diabetes. International Journal of Environmental Research and Public Health, 2020, 17, 207.	1.2	37
8	Appropriate Timing of Gestational Diabetes Mellitus Diagnosis in Medium- and Low-Risk Women: Effectiveness of the Italian NHS Recommendations in Preventing Fetal Macrosomia. Journal of Diabetes Research, 2020, 2020, 1-8.	1.0	26
9	MicroRNA-1281 as a Novel Circulating Biomarker in Patients With Diabetic Retinopathy. Frontiers in Endocrinology, 2020, 11, 528.	1.5	35
10	Obesity-related hypoxia via miR-128 decreases insulin-receptor expression in human and mouse adipose tissue promoting systemic insulin resistance. EBioMedicine, 2020, 59, 102912.	2.7	52
11	Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis. International Journal of Environmental Research and Public Health, 2020, 17, 3664.	1.2	47
12	Gestational diabetes and fetal overgrowth: time to rethink screening guidelines. Lancet Diabetes and Endocrinology,the, 2020, 8, 561-562.	5.5	32
13	Mediterranean Diet Nutrients to Turn the Tide against Insulin Resistance and Related Diseases. Nutrients, 2020, 12, 1066.	1.7	128
14	First Trimester Combined Test (FTCT) as a Predictor of Gestational Diabetes Mellitus. International Journal of Environmental Research and Public Health, 2019, 16, 3654.	1.2	24
15	Does a polarization state exist for mast cells in cancer?. Medical Hypotheses, 2019, 131, 109281.	0.8	9
16	Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus. Journal of Diabetes Research, 2019, 2019, 1-8.	1.0	31
17	Secretome Analysis of Hypoxiaâ€Induced 3T3â€L1 Adipocytes Uncovers Novel Proteins Potentially Involved in Obesity. Proteomics, 2018, 18, e1700260.	1.3	14
18	Comment on Li et al. HMGA1: A novel predisposing gene for acute myocardial infarction. International Journal of Cardiology, 2018, 256, 38.	0.8	0

#	Article	IF	Citations
19	High Mobility Group A (HMGA) proteins: Molecular instigators of breast cancer onset and progression. Biochimica Et Biophysica Acta: Reviews on Cancer, 2018, 1869, 216-229.	3.3	72
20	HMGA1 is a novel transcriptional regulator of the FoxO1 gene. Endocrine, 2018, 60, 56-64.	1.1	18
21	Postpartum Glucose Intolerance in Gestational Diabetes. , 2018, , 303-315.		0
22	Insulin and osteocalcin: further evidence for a mutual cross-talk. Endocrine, 2018, 59, 622-632.	1.1	43
23	Innate immunity in cardiac myxomas and its pathological and clinical correlations. Innate Immunity, 2018, 24, 47-53.	1.1	13
24	Postpartum glucose intolerance: an updated overview. Endocrine, 2018, 59, 481-494.	1.1	41
25	Barriers to Postpartum Glucose Intolerance Screening in an Italian Population. International Journal of Environmental Research and Public Health, 2018, 15, 2853.	1.2	10
26	Transcriptional Regulation of Glucose Metabolism: The Emerging Role of the HMGA1 Chromatin Factor. Frontiers in Endocrinology, 2018, 9, 357.	1.5	40
27	Type 2 Diabetes Mellitus and Cardiovascular Disease: Genetic and Epigenetic Links. Frontiers in Endocrinology, 2018, 9, 2.	1.5	228
28	Cross-talk among HMGA1 and FoxO1 in control of nuclear insulin signaling. Scientific Reports, 2018, 8, 8540.	1.6	9
29	HMGA1 and MMP-11 Are Overexpressed in Human Non-melanoma Skin Cancer. Anticancer Research, 2018, 38, 771-778.	0.5	9
30	Gestational diabetes mellitus: an updated overview. Journal of Endocrinological Investigation, 2017, 40, 899-909.	1.8	358
31	Pharmacogenetics in type 2 diabetes: still a conundrum in clinical practice. Expert Review of Endocrinology and Metabolism, 2017, 12, 155-158.	1.2	9
32	HMGA1 is a novel candidate gene for myocardial infarction susceptibility. International Journal of Cardiology, 2017, 227, 331-334.	0.8	33
33	Impact of Seasonality on Gestational Diabetes Mellitus. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2017, 17, 246-252.	0.6	28
34	Expression of matrix metalloproteinase-11 is increased under conditions of insulin resistance. World Journal of Diabetes, 2017, 8, 422.	1.3	20
35	Cooperation between HMGA1 and HIF-1 Contributes to Hypoxia-Induced VEGF and Visfatin Gene Expression in 3T3-L1 Adipocytes. Frontiers in Endocrinology, 2016, 7, 73.	1.5	29
36	A polymorphism of HMGA1 protects against proliferative diabetic retinopathy by impairing HMGA1-induced VEGFA expression. Scientific Reports, 2016, 6, 39429.	1.6	36

#	Article	IF	Citations
37	A new predictive tool for the early risk assessment of gestational diabetes mellitus. Primary Care Diabetes, 2016, 10, 315-323.	0.9	22
38	The Association between HMGA1 rs146052672 Variant and Type 2 Diabetes: A Transethnic Meta-Analysis. PLoS ONE, 2015, 10, e0136077.	1.1	17
39	A novel mechanism of post-translational modulation of HMGA functions by the histone chaperone nucleophosmin. Scientific Reports, 2015, 5, 8552.	1.6	16
40	Add-On Treatment with Liraglutide Improves Glycemic Control in Patients with Type 2 Diabetes on Metformin Therapy. Diabetes Technology and Therapeutics, 2015, 17, 468-474.	2.4	15
41	Early Effects of a Hypocaloric, Mediterranean Diet on Laboratory Parameters in Obese Individuals. Mediators of Inflammation, 2014, 2014, 1-8.	1.4	62
42	Evidence That anHMGA1Gene Variant Associates with Type 2 Diabetes, Body Mass Index, and High-Density Lipoprotein Cholesterol in a Hispanic-American Population. Metabolic Syndrome and Related Disorders, 2014, 12, 25-30.	0.5	45
43	Prevalence and predictors of postpartum glucose intolerance in Italian women with gestational diabetes mellitus. Diabetes Research and Clinical Practice, 2014, 105, 223-230.	1.1	63
44	Recent advances in the molecular genetics of type 2 diabetes mellitus. World Journal of Diabetes, 2014, 5, 128.	1.3	97
45	Cooperation between HMGA1, PDX-1, and MafA is Essential for Glucose-Induced Insulin Transcription in Pancreatic Beta Cells. Frontiers in Endocrinology, 2014, 5, 237.	1.5	41
46	Gestational Diabetes Mellitus: Screening and Outcomes in Southern Italian Pregnant Women. Isrn Endocrinology, 2013, 2013, 1-8.	2.0	29
47	Predictors of Postpartum Glucose Tolerance Testing in Italian Women with Gestational Diabetes Mellitus. Isrn Endocrinology, 2013, 2013, 1-6.	2.0	16
48	A polymorphism of HMGA1 is associated with increased risk of metabolic syndrome and related components. Scientific Reports, 2013, 3, 1491.	1.6	51
49	Transcriptional Regulation of the HMGA1 Gene by Octamer-Binding Proteins Oct-1 and Oct-2. PLoS ONE, 2013, 8, e83969.	1.1	8
50	Comment on: Marquez et al. Low-Frequency Variants inHMGA1Are Not Associated With Type 2 Diabetes Risk. Diabetes 2012;61:524â€“530. Diabetes, 2012, 61, e3-e3.	0.3	3
51	Insulin Resistance and Cancer Risk: An Overview of the Pathogenetic Mechanisms. Experimental Diabetes Research, 2012, 2012, 1-12.	3.8	408
52	HMGA1 is a novel downstream nuclear target of the insulin receptor signaling pathway. Scientific Reports, 2012, 2, 251.	1.6	50
53	The HMGA1-IGF-I/IGFBP System: A Novel Pathway for Modulating Glucose Uptake. Molecular Endocrinology, 2012, 26, 1578-1589.	3.7	41
54	Functional relationship between high mobility group A1 (HMGA1) protein and insulin-like growth factor-binding protein 3 (IGFBP-3) in human chondrocytes. Arthritis Research and Therapy, 2012, 14, R207.	1.6	12

#	Article	IF	Citations
55	Functional Variants of the <emph type="ital">HMGA1</emph> Gene and Type 2 Diabetes Mellitus. JAMA - Journal of the American Medical Association, 2011, 305, 903.	3.8	87
56	The Camp-HMGA1-RBP4 System. , 2011, , 175-197.		0
57	Pseudogene-mediated posttranscriptional silencing of HMGA1 can result in insulin resistance and type 2 diabetes. Nature Communications, 2010, 1, 40.	5.8	102
58	New Target Genes for the Peroxisome Proliferator-Activated Receptor-<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>Î³</mml:mi></mml:math>(PPAR<mml:math) Tj ETQq0 0 0 rgBT /Overlo Activity: Perspectives from the Insulin Receptor. PPAR Research, 2009, 2009, 1-8.	1.1	3
59	The cAMP-HMGA1-RBP4 system: a novel biochemical pathway for modulating glucose homeostasis. BMC Biology, 2009, 7, 24.	1.7	47
60	Transcriptional activity of the murine retinol-binding protein gene is regulated by a multiprotein complex containing HMGA1, p54nrb/NonO, protein-associated splicing factor (PSF) and steroidogenic factor 1 (SF1)/liver receptor homologue 1 (LRH-1). International Journal of Biochemistry and Cell Biology, 2009, 41, 2189-2203.	1.2	39
61	The insulin receptor: a new anticancer target for peroxisome proliferator-activated receptor-Â (PPARÂ) and thiazolidinedione-PPARÂ agonists. Endocrine-Related Cancer, 2008, 15, 325-335.	1.6	59
62	Activator Protein-2 Overexpression Accounts for Increased Insulin Receptor Expression in Human Breast Cancer. Cancer Research, 2006, 66, 5085-5093.	0.4	47
63	Lack of the architectural factor HMGA1 causes insulin resistance and diabetes in humans and mice. Nature Medicine, 2005, 11, 765-773.	15.2	204
64	Evaluation of a DHPLC-based assay for rapid detection of RET germline mutations in Italian patients with medullary thyroid carcinoma. Journal of Endocrinological Investigation, 2004, 27, 111-116.	1.8	4
65	A Nucleoprotein Complex Containing Sp1, C/EBPÎ², and HMGI-Y Controls Human Insulin Receptor Gene Transcription. Molecular and Cellular Biology, 2003, 23, 2720-2732.	1.1	123
66	Familial Medullary Thyroid Carcinoma: Clinical Variability and Low Aggressiveness Associated withRETMutation at Codon 804. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1674-1680.	1.8	86
67	Similarities and differences in the phenotype of members of an Italian family with hereditary non-autoimmune hyperthyroidism associated with an activating TSH receptor germline mutation. Journal of Endocrinological Investigation, 2002, 25, 696-701.	1.8	28
68	Increased expression of AP2 and Sp1 transcription factors in human thyroid tumors: a role in NIS expression regulation?. BMC Cancer, 2002, 2, 35.	1.1	107
69	RET proto-oncogene mutation in a mixed medullaryfollicular thyroid carcinoma. Journal of Endocrinological Investigation, 2001, 24, 51-55.	1.8	12
70	Transcriptional regulation of human insulin receptor gene by the highâ€mobility group protein HMGI(Y). FASEB Journal, 2001, 15, 492-500.	0.2	97
71	A Large Family with Hereditary MTC: Role of RET Genetic Analysis in Differential Diagnosis Between MEN 2A and FMTC. Hormone and Metabolic Research, 2001, 33, 52-56.	0.7	4
72	A Phe 486 Thyrotropin Receptor Mutation in an Autonomously Functioning Follicular Carcinoma that was Causing Hyperthyroidism. Thyroid, 2000, 10, 1009-1012.	2.4	57

#	Article	IF	Citations
73	The 3â€²,5â€²-Cyclic Adenosine Monophosphate Response Element Binding Protein (CREB) Is Functionally Reduced in Human Toxic Thyroid Adenomas1. Endocrinology, 2000, 141, 722-730.	1.4	20
74	A Novel Mutation in the Thyrotropin (TSH) Receptor Gene Causing Loss of TSH Binding But Constitutive Receptor Activation in a Family with Resistance to TSH. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4238-4242.	1.8	46
75	Iodide symporter gene expression in normal and transformed rat thyroid cells. European Journal of Endocrinology, 1999, 140, 447-451.	1.9	65
76	A Val 677 Activating Mutation of the Thyrotropin Receptor in a HÃ¼rthle Cell Thyroid Carcinoma Associated with Thyrotoxicosis. Thyroid, 1999, 9, 13-17.	2.4	67
77	Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma. Journal of Endocrinological Investigation, 1998, 21, 358-364.	1.8	42
78	Iodide Symporter Gene Expression in Human Thyroid Tumors1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2493-2496.	1.8	126
79	Thyroid hyperfunctioning adenomas with and without Gsp/TSH receptor mutations show similar clinical features. Experimental and Clinical Endocrinology and Diabetes, 1998, 106, 234-236.	0.6	22
80	Iodide Symporter Gene Expression in Human Thyroid Tumors. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2493-2496.	1.8	112
81	A Case of Metastatic Medullary Thyroid Carcinoma: Early Identification Before Surgery of anRETProto-Oncogene Somatic Mutation in Fine-Needle Aspirate Specimens¹. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3378-3382.	1.8	16
82	Molecular insights into TSH receptor abnormality and thyroid disease. Journal of Endocrinological Investigation, 1997, 20, 36-47.	1.8	43
83	A Case of Metastatic Medullary Thyroid Carcinoma: Early Identification Before Surgery of an RET Proto-Oncogene Somatic Mutation in Fine-Needle Aspirate Specimens. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3378-3382.	1.8	14